{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:16:42Z","timestamp":1791422202517,"version":"4.3.3"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1097\/coc.0b013e318287bbae","type":"journal-article","created":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T14:16:43Z","timestamp":1364393803000},"page":"61-67","source":"Crossref","is-referenced-by-count":32,"title":["Phase II Study of Nab-Paclitaxel and Bevacizumab as First-line Therapy for Patients with Unresectable Stage III and IV Melanoma"],"prefix":"10.1097","volume":"38","author":[{"given":"Lynn E.","family":"Spitler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Boasberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven O\u2019","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Cruickshank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Mesko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210128","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1200\/JCO.2004.04.165","article-title":". Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.","volume":"22","author":"Avril","year":"2004","journal-title":"J Clin Oncol"},{"key":"R2-12-20210128","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1200\/JCO.2006.06.0483","article-title":". Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.","volume":"24","author":"Bedikian","year":"2006","journal-title":"J Clin Oncol"},{"key":"R3-12-20210128","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":". Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.","volume":"17","author":"Chapman","year":"1999","journal-title":"J Clin Oncol"},{"key":"R4-12-20210128","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":". Improved survival with vemurafenib in melanoma with BRAF V600E mutation.","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"R5-12-20210128","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":". Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"R6-12-20210128","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":". Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"R7-12-20210128","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":". Improved survival with ipilimumab in patients with metastatic melanoma.","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R9-12-20210128","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00008390-199304000-00002","article-title":"The possible role of angiogenesis in the metastatic potential of human melanoma. Clinicopathological aspects.","volume":"3","author":"Denijn","year":"1993","journal-title":"Melanoma Res"},{"key":"R11-12-20210128","first-page":"595","article-title":"Angiogenesis is prognostically important in vertical growth phase melanomas.","volume":"15","author":"Straume","year":"1999","journal-title":"Int J Oncol"},{"key":"R12-12-20210128","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00008390-199908000-00006","article-title":". Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients.","volume":"9","author":"Birck","year":"1999","journal-title":"Melanoma Res"},{"key":"R13-12-20210128","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/bjc.1997.486","article-title":"Enhanced expression of vascular endothelial growth factor in metastatic melanoma.","volume":"76","author":"Salven","year":"1997","journal-title":"Br J Cancer"},{"key":"R14-12-20210128","first-page":"172","article-title":". Expression of vascular permeability factorvascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis.","volume":"56","author":"Claffey","year":"1996","journal-title":"Cancer Res"},{"key":"R15-12-20210128","first-page":"4932","article-title":"Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.","volume":"60","author":"Rofstad","year":"2000","journal-title":"Cancer Res"},{"key":"R16-12-20210128","doi-asserted-by":"crossref","first-page":"e38364","DOI":"10.1371\/journal.pone.0038364","article-title":". Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension.","volume":"7","author":"Schuster","year":"2012","journal-title":"PLoS One"},{"key":"R17-12-20210128","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1245\/s10434-011-2027-2","article-title":". Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.","volume":"19","author":"Kruijff","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"R18-12-20210128","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00008390-200410000-00013","article-title":"The role of taxanes in the treatment of metastatic melanoma.","volume":"14","author":"Gogas","year":"2004","journal-title":"Melanoma Res"},{"key":"R19-12-20210128","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<79::AID-CNCR12>3.0.CO;2-L","article-title":". Paclitaxel and tamoxifen: an active regimen for patients with metastatic melanoma.","volume":"88","author":"Nathan","year":"2000","journal-title":"Cancer"},{"key":"R20-12-20210128","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/cncr.21611","article-title":". Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma.","volume":"106","author":"Rao","year":"2006","journal-title":"Cancer"},{"key":"R23-12-20210128","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":". Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"R24-12-20210128","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","article-title":". Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.","volume":"30","author":"Socinski","year":"2012","journal-title":"J Clin Oncol"},{"key":"R25-12-20210128","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cncr.24720","article-title":". A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.","volume":"116","author":"Hersh","year":"2010","journal-title":"Cancer"},{"key":"R26-12-20210128","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/cncr.25659","article-title":"3rd, et al.. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E(1).","volume":"117","author":"Kottschade","year":"2011","journal-title":"Cancer"},{"key":"R27-12-20210128","first-page":"863","article-title":". Phase 3, randomized, open-label, multicenter trial of nab-paclitaxel (nab-P) vs dacarbazine (DTIC) in previously untreated patients with metastatic malignant melanoma (MMM). Presented at annual meeting of the Society for Melanoma Research, 2012.","volume":"25","author":"Hersh","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"R28-12-20210128","doi-asserted-by":"crossref","first-page":"7781","DOI":"10.1158\/1078-0432.CCR-08-0243","article-title":". Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.","volume":"14","author":"Mabuchi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R29-12-20210128","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1200\/JCO.2008.16.3212","article-title":". Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).","volume":"26","author":"Grothey","year":"2008","journal-title":"J Clin Oncol"},{"key":"R30-12-20210128","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":". Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"key":"R31-12-20210128","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1634\/theoncologist.2008-0016","article-title":". Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage.","volume":"13","author":"Stein","year":"2008","journal-title":"Oncologist"},{"key":"R32-12-20210128","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":". New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R33-12-20210128","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":". Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin Oncol"},{"key":"R35-12-20210128","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"R36-12-20210128","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time.","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"R37-12-20210128","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":". Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"R39-12-20210128","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.1983.1.2.126","article-title":". A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III).","volume":"1","author":"Balch","year":"1983","journal-title":"J Clin Oncol"},{"key":"R40-12-20210128","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2345::AID-CNCR8>3.0.CO;2-K","article-title":". Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors.","volume":"79","author":"Brand","year":"1997","journal-title":"Cancer"},{"key":"R41-12-20210128","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1200\/JCO.2000.18.22.3782","article-title":". Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials.","volume":"18","author":"Manola","year":"2000","journal-title":"J Clin Oncol"},{"key":"R42-12-20210128","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":". Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"R43-12-20210128","first-page":"864","article-title":"R, Gergich K, Cong C, et al.. Efficacy And Safety Of MK-3475 In Patients With Advanced Melanoma. Presented at the annual meeting of the Society for Melanoma Research, 2012.","volume":"25","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"R44-12-20210128","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":". Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"R45-12-20210128","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":". Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"R46-12-20210128","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":". Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"R47-12-20210128","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":". Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"R48-12-20210128","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":". Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"R49-12-20210128","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cncr.27760","article-title":". A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N0775.","volume":"119","author":"Kottschade","year":"2013","journal-title":"Cancer"},{"key":"R50-12-20210128","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/annonc\/mdr126","article-title":". First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 5007).","volume":"23","author":"von Moos","year":"2012","journal-title":"Ann Oncol"},{"key":"R51-12-20210128","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000138351","article-title":". Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma.","volume":"74","author":"Gonzalez-Cao","year":"2008","journal-title":"Oncology"},{"key":"R52-12-20210128","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1200\/JCO.2011.34.6270","article-title":". BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.","volume":"30","author":"Kim","year":"2012","journal-title":"J Clin Oncol"},{"key":"R53-12-20210128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/cncr.23987","article-title":". Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.","volume":"115","author":"Perez","year":"2009","journal-title":"Cancer"},{"key":"R54-12-20210128","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1593\/neo.08302","article-title":". Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy.","volume":"10","author":"Volk","year":"2008","journal-title":"Neoplasia"},{"key":"R55-12-20210128","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1593\/neo.101490","article-title":". Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases.","volume":"13","author":"Volk","year":"2011","journal-title":"Neoplasia"},{"key":"R56-12-20210128","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nnano.2012.45","article-title":". Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner.","volume":"7","author":"Chauhan","year":"2012","journal-title":"Nat Nanotechnol"},{"key":"R57-12-20210128","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1593\/tlo.09109","article-title":". SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients.","volume":"2","author":"Desai","year":"2009","journal-title":"Transl Oncol"},{"key":"R58-12-20210128","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":". Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase III trial.","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J Clin Oncol"},{"key":"R59-12-20210128","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/1523-1747.ep12334263","article-title":". The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma.","volume":"108","author":"Ledda","year":"1997","journal-title":"J Invest Dermatol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0b013e318287bbae","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T01:39:44Z","timestamp":1715132384000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201502000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e318287bbae","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}